Genetically modified t cells take on rare sarcomas
NCT ID NCT04044768
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a one-time infusion of a patient's own immune cells that have been genetically modified to recognize and attack cancer cells. It is for people with advanced synovial sarcoma or myxoid liposarcoma whose tumors have a specific marker (MAGE-A4) and who have already tried standard chemotherapy. The main goal is to see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- afamitresgene autoleucel (ADP-A2M4) – a patient's own immune cells genetically modified to target cancer
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced synovial sarcoma or myxoid liposarcoma who have few alternatives.
- What could go wrong
- This is a small, early-phase trial (52 participants) with no control group. The treatment may cause serious side effects, and it is not yet proven to work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYXOID LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Leon Berard
Lyon, France
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fred Hutch
Seattle, Washington, 98109, United States
-
Gustave Roussy Cancer Center
Villejuif, 94805, France
-
Hospital Haut Leveque, CHU Bordeaux
Pessac, 33604, France
-
Hospital Universitari Vall D'Hebron
Barcelona, Catalonia, 119-129, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 33612, United States
-
Medical College of WI Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
National Cancer Institute
Bethesda, Maryland, 20892, United States
-
Northwestern University Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, 60611, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Stanford Cancer Center
Palo Alto, California, 94305, United States
-
Start Madrid-FJD, Fundación Jimѐnez Díaz
Madrid, 28040, Spain
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
UCLH Cancer Clinical Trials Unit
London, NW1 2PG, United Kingdom
-
University of Colorado
Aurora, Colorado, 80045, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
-
Vanderbilt
Nashville, Tennessee, 37212, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a genetic marker guide future cancer therapies in taiwan?
- New immunotherapy targets rare cancers by harnessing the Body's immune system
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New pill may keep soft tissue sarcoma in check after chemo
- New registry aims to unlock secrets of rare sarcoma
- Glow-in-the-Dark dye could help surgeons find hidden lung cancer in teens